Clinical Trials

1,000 enrolled

Breast Neoplasms

NCT07062965 2026-04-16

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

400 enrolled

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT07085767 2026-04-16

OPERA-02

1,000 enrolled

Breast Neoplasms

NCT07229313 2026-04-16

A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors

BreastGastrointestinalGynecologicHead & NeckSarcomaThoracic

76 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT05877599 2026-04-15

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

BreastGastrointestinalGynecologicHead & NeckThoracic

45 enrolled

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Colorectal Neoplasms

NCT06120283 2026-04-15

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

399 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06324357 2026-04-15

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

768 enrolled

BreastGastrointestinal

Adenocarcinoma Of Esophagus, Breast Neoplasms, Colorectal Neoplasms

NCT07222267 2026-04-15

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

86 enrolled

Breast Neoplasms

NCT07243002 2026-04-15

REPOWER

Recruiting

3,000 enrolled

Breast Neoplasms

NCT05238922 2026-04-14

Study of INCB123667 in Subjects With Advanced Solid Tumors

BreastGastrointestinalGynecologic

604 enrolled

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Digestive System Neoplasms

NCT05377996 2026-04-14

A Study of XMT-1660 in Participants With Solid Tumors

319 enrolled

BreastGynecologic

Breast Neoplasms, Carcinoma, Adenoid Cystic, Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05827081 2026-04-14

Adjuvant WIDER

1,400 enrolled

Breast Neoplasms, Breast Neoplasms, Male

NCT07311993 2026-04-14

Phase 1 Study of CLR 125 in Triple Negative Breast Cancer

60 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05774951 2026-04-13

CAMBRIA-1

4,300 enrolled

Breast Neoplasms

NCT06253871 2026-04-13

A Phase 1/1b Study of IAM1363 in HER2 Cancers

BreastCNSGastrointestinalThoracic

383 enrolled

Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms, Stomach Neoplasms

NCT06582017 2026-04-13

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

BreastGastrointestinalGenitourinaryGynecologicThoracic

100 enrolled

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Gastrointestinal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT06625775 2026-04-13

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

BreastGastrointestinalThoracic

392 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT06746688 2026-04-13

A First-in-human, Clinical Trial Assessing the Safety of ES2B-C001-S01 With or Without [Adjuvant] in Patients With HER2-expressing Metastatic Breast Cancer.

40 enrolled

Breast Neoplasms

NCT06810804 2026-04-13

A Phase IIa Study to Evaluate NBQ72S

10 enrolled

Breast Neoplasms

NCT07007559 2026-04-13

ASPEN-09-03

120 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT07368998 2026-04-13

optINAVO

80 enrolled

Breast Neoplasms

NCT07408089 2026-04-13

KOMODO-1

96 enrolled

Breast Neoplasms

NCT07524855 2026-04-13

HLD-0117

33 enrolled

Breast Neoplasms

NCT06695845 2026-04-09

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

200 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Esophageal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05950945 2026-04-08

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

250 enrolled

Breast Neoplasms

NCT06562192 2026-04-08

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

BreastGastrointestinalThoracic

162 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT06760819 2026-04-08

panSOHO

BreastGastrointestinalGenitourinaryGynecologicSarcoma

111 enrolled

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors

NCT07214532 2026-04-08

SIGNAL-ER 101

Phase NA Recruiting

725 enrolled

Breast Neoplasms, Carcinoma, Ductal, Breast

NCT05579366 2026-04-07

RAINFOL-01

BreastGynecologicOther solid neoplasmThoracic

764 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Fallopian Tube Neoplasms, Mesothelioma, Ovarian Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05696626 2026-04-07

ELAINEIII

500 enrolled

Breast Neoplasms

NCT06072612 2026-04-07

BRIA-ABC

404 enrolled

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT06966453 2026-04-07

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

100 enrolled

Breast Neoplasms

NCT07216105 2026-04-07

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

BreastGastrointestinalGynecologicHead & NeckThoracic

113 enrolled

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT07424547 2026-04-07

Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

BreastGenitourinaryGynecologicThoracic

386 enrolled

Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT05386108 2026-04-06

ELECTRA

73 enrolled

BreastCNS

Brain Diseases, Brain Neoplasms, Breast Diseases, Breast Neoplasms, Central Nervous System Diseases, Neoplasms, Neoplasms by Site, Central Nervous System Neoplasms

NCT05785741 2026-04-06

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

BreastHead & NeckThoracic

1,000 enrolled

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06274515 2026-04-06

REMERGE

Phase 4 Recruiting

320 enrolled

Breast Neoplasms

NCT07405801 2026-04-06

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

80 enrolled

Breast Neoplasms

NCT07510802 2026-04-06

Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC

60 enrolled

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05458674 2026-04-03

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

30 enrolled

Breast Neoplasms

NCT06790693 2026-04-03

INAVO123

450 enrolled

Breast Neoplasms

NCT07214662 2026-04-03

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer

136 enrolled